Does the efficacy of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors vary by age and sex among individuals with type 2 diabetes? This evidence concerns the gene GLP1R and type 2 diabetes mellitus.